Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates

Several healthcare and biotech stocks experienced notable after-hours gains following corporate announcements. Pulmonx Corp. (LUNG) surged 33.33% on preliminary Q3 2025 revenue of $21.5 million and key executive appointments. Universal Health Services Inc. (UHS) climbed 7.41% after reporting Q3 results, revising its 2025 operating forecast, and authorizing a $1.5 billion increase to its stock repurchase program. X4 Pharmaceuticals Inc. (XFOR) gained 5.35% following the completion of an underwritten public offering that raised approximately $155.3 million in gross proceeds.

Analysis

Pulmonx Corp. (LUNG) experienced a significant after-hours surge of 33.33% following the announcement of preliminary, unaudited third-quarter 2025 revenue of approximately $21.5 million. This positive revenue signal was coupled with a leadership restructuring, as Glen French was reappointed President and CEO, and Derrick Sung named COO and CFO, effective November 3. The company also rescheduled its full Q3 financial results release to November 12, 2025.

Universal Health Services Inc. (UHS) climbed 7.41% after reporting its third-quarter results and revising its full-year 2025 operating forecast. Further bolstering investor confidence, the Board of Directors authorized a substantial $1.5 billion increase to its stock repurchase program on October 27, signaling a commitment to enhancing shareholder value. This capital allocation decision indicates management's positive outlook on the company's long-term prospects.

X4 Pharmaceuticals Inc. (XFOR) gained 5.35% following the successful completion of an underwritten public offering, which generated gross proceeds of approximately $155.3 million before expenses. This offering involved 52.8 million shares and pre-funded warrants for 700,000 shares, increasing total shares outstanding to 79.2 million. The broader healthcare and biotech sector demonstrated strength, with several stocks experiencing notable after-hours gains, reflecting a generally positive market sentiment for companies with specific catalysts.

Key Decisions for Investors

• Investors should monitor Pulmonx Corp.'s upcoming Q3 2025 earnings release on November 12 for confirmation of preliminary revenue figures and further details on the new leadership's strategic direction.
• Consider Universal Health Services Inc.'s increased stock repurchase program as a strong signal of management confidence and potential for enhanced shareholder returns, warranting a review of its revised 2025 operating forecast.
• Evaluate the impact of X4 Pharmaceuticals Inc.'s recent capital raise on its balance sheet and operational runway, while acknowledging the potential for dilution given the increase in shares outstanding to 79.2 million.